Vitravene™

Company
Isis Pharmaceuticals, Inc.
Use
Inhibition of CMV eye infections
Features
First antisense therapeutic approved for use in humans
NIH Contribution
Discovery that using phosphorothioate oligonucleotides as DNA backbones results in effective anti-viral compounds that are more stable in human cells
Success Stories
http://www.ott.nih.gov/pdfs/VitraveneCS.pdf
Approval Type
FDA
HHS Institute/Agency
NCI
Inventor(s)
J. Cohen
Year
1998
Tech Cat
Therapeutic

Request More Info

L-038-1988